Jasper Therapeutics posts $18.7 million net loss for third quarter 2025
Reuters
Nov 10
<a href="https://laohu8.com/S/JSPR">Jasper Therapeutics</a> posts $18.7 million net loss for third quarter 2025
Jasper Therapeutics Inc. reported a net loss of $18.7 million, or $1.13 per share, for the three months ended September 30, 2025. Research and development expenses were $14.4 million, while general and administrative expenses totaled $4.8 million. The company held $50.9 million in cash and cash equivalents as of September 30, 2025. During the quarter, Jasper completed a $30 million underwritten offering of common stock and warrants, extending its cash runway through the first half of 2026. Jasper continued enrollment in the BEACON and open-label extension studies for its briquilimab antibody therapy and provided updates on investigations into previously reported efficacy results. The Phase 2b study for chronic spontaneous urticaria is expected to begin in mid-2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572025-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.